Analysts Set Pharvaris N.V. (NASDAQ:PHVS) Target Price at $40.56

Pharvaris N.V. (NASDAQ:PHVS) has been given an average rating of “Moderate Buy” by the twelve research firms that are presently covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $40.5556.

Several brokerages recently weighed in on PHVS. Wedbush boosted their target price on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research note on Thursday. Guggenheim upped their target price on Pharvaris from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Thursday, December 4th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Pharvaris in a research note on Wednesday, December 3rd. Finally, Leerink Partners set a $38.00 price objective on Pharvaris in a report on Wednesday, December 3rd.

Pharvaris Stock Performance

Shares of PHVS stock opened at $27.98 on Thursday. The company’s 50-day simple moving average is $25.74 and its two-hundred day simple moving average is $23.70. Pharvaris has a one year low of $11.51 and a one year high of $29.80.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.08. On average, analysts anticipate that Pharvaris will post -2.71 EPS for the current fiscal year.

Institutional Trading of Pharvaris

A number of hedge funds and other institutional investors have recently made changes to their positions in PHVS. Palumbo Wealth Management LLC boosted its holdings in Pharvaris by 3.2% in the second quarter. Palumbo Wealth Management LLC now owns 14,549 shares of the company’s stock valued at $256,000 after purchasing an additional 447 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in shares of Pharvaris by 30.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the period. HighVista Strategies LLC boosted its stake in shares of Pharvaris by 4.3% in the second quarter. HighVista Strategies LLC now owns 23,739 shares of the company’s stock worth $418,000 after buying an additional 971 shares during the last quarter. California State Teachers Retirement System grew its holdings in Pharvaris by 9.8% during the second quarter. California State Teachers Retirement System now owns 14,048 shares of the company’s stock worth $247,000 after acquiring an additional 1,257 shares during the period. Finally, Legal & General Group Plc grew its holdings in Pharvaris by 17.2% during the second quarter. Legal & General Group Plc now owns 11,550 shares of the company’s stock worth $203,000 after acquiring an additional 1,695 shares during the period.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.